K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Am J Kidney Dis 41(Suppl 3): S38, 2003 with permission from the National Kidney Foundation;1 accessed http:// www.kidney.org/professionals/kdoqi/guidelines_dyslipidemia/pdf/ajkd_dyslipidemia_ gls.pdf K Perform time-dependent analysis of lipid values for risk prediction. Since lipid levels show considerable changes during the various stages of CKD, it might be interesting to see whether a data analysis considering all measured values during the entire observation period is more predictive than the classical analysis with one measure- ment at baseline of a certain CKD stage. K Investigate whether the association between serum TGs and risk varies meaningfully as a function of fasting status. K Investigate the independent association between Lp(a), apoB and cardiovascular outcomes in large prospec- tive studies of people with CKD. It should further be investigated whether knowledge of high Lp(a), non-HDL- C, and/or apoB values has any influence on the manage- ment of other risk factors and whether this has an influence on outcomes. DISCLAIMER While every effort is made by the publishers, editorial board, and ISN to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor, copyright holder, or advertiser concerned. Accordingly, the publishers and the ISN, the editorial board and their respective employers, office and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. While every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, and described within this Journal, should only be followed in conjunction with the drug manufacturer s own published literature. 